$GRI News

Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $32

GRI Bio Q1 EPS $(1.61) Misses $(0.91) Estimate

GRI Bio Receives Notice Of Allowance From UAE Patent Office For UAE Patent Titled Prevention And Treatment Of Inflammatory Conditions

Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $40

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

GRI stock has given up its prior gain. GRI Bio shares were trading higher. The company reported FY25 financial results.

GRI stock has given up its prior gain. GRI Bio shares were trading higher. The company reported FY25 financial results.

GRI Bio shares are trading higher. The company reported FY25 financial results.

GRI Bio FY25 Net Loss $12M

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

GRI Bio shares are trading higher after the company announced data from its recently completed Phase 2a clinical study of GRI-0621 in Idiopathic Pulmonary Fibrosis

GRI Bio Meets Primary Endpoint In Phase 2a Study; Met Multiple Secondary Endpoints; Showed Improvement On Exploratory Endpoint

GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

U.S. Patent And Trademark Office Issues GRI Bio U.S. Patent No. 12,528,775

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

GRI Bio Announces Reverse Stock Split

GRI Bio shares are trading lower after the company announced it approved a 1-for-28 reverse stock split.

GRI Bio Board Approves 1-For-28 Reverse Stock Split, Effective Jan. 23